Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) will report first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET.
Access the live audio webcast and slides via the Investors Events & Presentations page or use Conference ID Syndax1Q26 with domestic dial-in 800-590-8290 or international dial-in 240-690-8800. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
In the Apr 24 session, SNDX gained 1.86%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings date notice | Neutral | +1.9% | Announced Q4 and FY2025 results date and associated conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The only prior earnings-date/conference notice in the last six months saw a modestly positive +1.88% reaction, suggesting such scheduling updates have not historically driven sharp volatility.
Over recent months, Syndax has transitioned into a commercial-stage oncology company with two FDA‑approved medicines and growing revenue, highlighted by Q4 2025 and FY2025 results and detailed 10‑K and 8‑K disclosures. Alongside this, the company has regularly communicated logistics for earnings calls, including the prior notice on Feb 19, 2026 for its Q4/FY2025 results, which coincided with a +1.88% move. Today’s Q1 2026 earnings date announcement fits this pattern of consistent investor communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax1Q26
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-1q26.open-exchange.net
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
